Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Ejhaem|May 1, 2025
Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of IrelandEdmund C R Watson, Faouzi Djebbari, Fotios Panitsas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2020
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell LymphomaLeo I Gordon, Jason B Kaplan, Rakesh Popat, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 StudyThomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
American Journal of Hematology|June 18, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)Heinz Ludwig, Evangelos Terpos, Francesca Gay, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapyLydia Lee, Wen Chean Lim, Daria Galas-Filipowicz, et al.
Blood Cancer Journal|April 2, 2025
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group StudyCarlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, et al.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
Oncotarget|January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Pageof 9